Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.

• US 5,830,753 A
• Filed: 09/30/1994
• Issued: 11/03/1998
• Est. Priority Date: 09/30/1994
• Status: Expired due to Term

• Current Assignee: Ludwig Institute for Cancer Research, Ltd.
• Original Assignee: Ludwig Institute for Cancer Research, Ltd.
• Inventors: Ikeda, Hideyuki, Boon-Falleur, Thierry, Coulie, Pierre
• Primary Examiner(s): Feisee, Lila
• Assistant Examiner(s): Davis, Minh-Tam
• Application Number:
  US08/316,231
• Time in Patent Office: 1,495 Days
• Field of Search: 536/23.5, 435/69.1, 435/325, 435/320.1, 435/252.3, 935/9, 935/70, 935/71, 530/350
• US Class Current: 435/325
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y10S 530/828 Cancer

Abstract

A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.

Claims

1. An isolated nucleic acid molecule that encodes for a DAGE tumour rejection antigen precursor as defined by the nucleotide sequence set forth in SEQ. ID. NO:

1.

3. An isolated MRNA molecule which is complementary to the nucleic acid molecule of claim 1, and codes for a tumor rejection antigen precursor of SEQ ID No:

1.

4. A host cell transfected or transformed with the nucleic acid molecule of claim 1.

6. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.

8. The host cell of claim 4, wherein said host cell is a mammalian cell which expresses HLA-A24.

10. The expression vector of claim 6, further comprising a nucleic acid molecule which codes for HLA-A24.

12. Expression kit comprising a separate portion of each of:

(i) the isolated nucleic acid molecule of claim 1, and

(ii) a nucleic acid molecule which codes for HLA-A24.

14. An isolated tumor rejection antigen precursor coded by the nucleic acid molecule of claim 1, or 2.

2. An isolated nucleic acid molecule which hybridizes, under stringent conditions, to the nucleic acid molecule set forth in SEQ ID No:

1, and codes for a tumor rejection antigen precursor, with the proviso that said isolated nucleic acid molecule does not code for any of;

a MAGE tumor rejection antigen precursor, a BAGE tumor rejection antigen precursor, a GAGE tumor rejection antigen precursor.

5. A host cell transfected or transformed with the nucleic acid molecule of claim 2.

7. An expression vector comprising the isolated nucleic acid molecule of claim 2 operably linked to a promoter.

9. The host cell of claim 5, wherein said host cell is a mammalian cell which expresses HLA-A24.

11. The expression vector of claim 7, further comprising a nucleic acid molecule which codes for HLA-A24.

13. Expression kit comprising a separate portion of each of:

(i) the isolated nucleic acid molecule of claim 2, and;

(ii) a nucleic acid molecule which codes for HLA-A24.